Triad Clinical Trials | Greensboro, NC

Research site

(Unclaimed)

Location

811 Dolley Madison Road, Greensboro, North Carolina, United States of America

Site insights

Top conditions

Top treatments

Relamorelin

Simufilam

Testosterone

Metformin

SEL-212

AR1001

MTX

CAD106

CNP520

Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 33 total trials

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling

Diabetic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 1 or 2

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting

Respiratory Syncytial Virus

Drug: Placebo

Drug: mRNA-1345

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

This Phase 2a clinical trial will evaluate the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV8...

Enrolling

Coronary Heart Disease

Drug: DFV890

Drug: Placebo

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Enrolling

Gout

Drug: Methotrexate

Biological: Pegloticase

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (APOLLOE4-LTE)

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 ge...

Invitation-only

Early Alzheimer's Disease

Drug: Experimental: ALZ-801

Open-label Extension for Phase 3 Clinical Trials of Simufilam

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Active, not recruiting

Alzheimer Disease

Drug: Simufilam

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease (Polaris-AD)

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling

Alzheimer Disease

Drug: Placebo

Drug: AR1001

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (EURELIA2)

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling

Hyperuricemia

Tophi

Drug: Allopurinol

Drug: Tigulixostat

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients (EURELIA1)

The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety o...

Enrolling

Hyperuricemia

Gout Flare

Drug: Placebo

Drug: Tigulixostat